ӳ��ý

Cancer Program

Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA.

Parsons HA, Messer C, Santos K, et al. Detection of heterogeneous resistance mechanisms to tyrosine kinase inhibitors from cell-free DNA. Cell genomics. 2025:100987. doi:10.1016/j.xgen.2025.100987

Genomic landscape and immunological profile of glioblastoma in East Asian patients.

Zhong S, Wu B, Dubois F, et al. Genomic landscape and immunological profile of glioblastoma in East Asian patients. Cell reports. Medicine. 2025;6(8):102217. doi:10.1016/j.xcrm.2025.102217

Integrative genomic identification of therapeutic targets for pancreatic cancer.

Guo JA, Gong D, Evans K, et al. Integrative genomic identification of therapeutic targets for pancreatic cancer. Cell reports. 2025;44(9):116191. doi:10.1016/j.celrep.2025.116191

MYC amplification and MYC protein expression are poor prognostic markers in pediatric and young adult osteosarcoma.

Nagy MR, Puopolo O, Alston E, et al. MYC amplification and MYC protein expression are poor prognostic markers in pediatric and young adult osteosarcoma. Cancer. 2025;131(22):e70161. doi:10.1002/cncr.70161

CRISPR-based therapeutic genome editing for inherited blood disorders.

Levesque S, Bauer DE. CRISPR-based therapeutic genome editing for inherited blood disorders. Nature reviews. Drug discovery. 2025. doi:10.1038/s41573-025-01236-y

SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors.

Lightbody ED, Sklavenitis-Pistofidis R, Wu T, et al. SWIFT-seq enables comprehensive single-cell transcriptomic profiling of circulating tumor cells in multiple myeloma and its precursors. Nature cancer. 2025. doi:10.1038/s43018-025-01006-0

In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma.

Knudsen NH, Escobar G, Korell F, et al. In vivo CRISPR screens identify modifiers of CAR T cell function in myeloma. Nature. 2025. doi:10.1038/s41586-025-09489-8

Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation.

Słabicki M. Expanding the druggable zinc-finger proteome defines properties of drug-induced degradation. Molecular cell. 2025;85(16):3184-3201.e14. doi:10.1016/j.molcel.2025.07.019

A multimodal whole-slide foundation model for pathology.

Ding T, Wagner SJ, Song AH, et al. A multimodal whole-slide foundation model for pathology. Nature medicine. 2025. doi:10.1038/s41591-025-03982-3

In vivo CRISPR screening in head and neck cancer reveals Uchl5 as an immunotherapy target.

Fu C, Saddawi-Konefka R, Chinai JM, et al. In vivo CRISPR screening in head and neck cancer reveals Uchl5 as an immunotherapy target. Nature communications. 2025;16(1):8572. doi:10.1038/s41467-025-63592-y